Halozyme Says US FDA Approves Rybrevant Faspro Co-Formulated With Enhanze to Treat Head, Neck Cancer

10:25 AM EST, 11/06/2026 (MT Newswires) -- Halozyme Therapeutics (HALO) said Friday that Johnson & Johnson (JNJ) was given accelerated approval by the US Food and Drug Administration for Rybrevant Faspro, co-formulated with Halozyme's Enhanze, to treat adults with head and neck squamous cell carcinoma. The approval covers patients with recurrent or metastatic head and neck squamous cell cancer whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody, Halozyme said. Price: 107.86, Change: -15.10, Percent Change: -12.28